3SBio, Inc. ( (TRSBF) ) has released its Q4 earnings. Here is a breakdown of the information 3SBio, Inc. presented to its investors.
3SBio, Inc. is a leading biotechnology company based in China, specializing in the development, production, and sale of biopharmaceutical products, with a strong market presence in the treatment of thrombocytopenia and anemia. In its latest earnings report for the year ended December 31, 2024, 3SBio, Inc. reported a significant increase in revenue and profits, with revenue rising by 16.5% to RMB9,108.0 million and net profit attributable to owners of the parent increasing by 34.9% to RMB2,090.3 million. The company also saw a notable rise in EBITDA, which grew by 32.8% to RMB3,173.8 million, reflecting strong operational performance. Key strategic developments included the approval of Mandi Foam for market launch, the expansion of TPIAO’s indications, and several strategic partnerships aimed at enhancing product offerings and market reach. Looking ahead, 3SBio, Inc. remains focused on expanding its therapeutic coverage and maintaining its market leadership through continued innovation and strategic collaborations.